Securing Radiopharma and GLP-1 Supply Chains Through 2026 Mergers and Acquisitions

The pharmaceutical industry is currently experiencing a shift towards a capability-led strategy, focusing more on platforms and production capacity rather than the acquisition of intellectual property. According to the recent Global M&A Report 2026 released by Bain & Company, this change is evident in the resurgence of deal values, which reached $4.9 trillion in 2025. The report indicates that 80% of industry executives expect M&A activity to either remain stable or increase in the near future. Strategic deals within the pharmaceutical and biotechnology sectors have also seen a significant boost, with average deal sizes increasing by over 80%. Suzanne Kumar, an executive vice president at Bain & Company, highlighted the industry’s transition towards securing platforms and production capacity rather than solely focusing on intellectual property acquisitions.

Vertical integration has become a key focus for industry leaders, especially in specialized areas like radio pharma. More than 80% of deals in the field of radio pharma in 2025 integrated manufacturing or isotope supply, showcasing a preference for ensuring capacity security over simple pipeline expansion. This shift is being driven by the growing complexity of biologics and the fragile nature of supply chains, which highlight the importance of direct control over production processes to expedite time-to-market. The trend towards securing scarce inputs like isotopes and sterile fill-finish capabilities illustrates a strategic move towards mitigating bottlenecks rather than merely addressing operational requirements.

The emphasis on vertical integration extends to the development of glucagon-like peptide-1 (GLP-1) obesity treatments, where the industry is shifting focus towards owning next-generation delivery platforms and multi-agonist molecules alongside manufacturing capacities. The strategic advice for 2026 is to look beyond the molecule itself and prioritize delivery innovation and scalable production. Decisions regarding ownership of end-to-end capabilities or partnerships now depend on which parts of the value chain offer a competitive edge.

In the realm of antibody-drug conjugates (ADCs), acquiring access to differentiated science takes precedence over scale. With ADCs accounting for about 40% of all antibody transactions, it is crucial to secure unique payloads and novel linker technologies for sustainable scientific advantage. Leading acquirers are striking a balance between speed and flexible partnerships to access innovation without bearing the full risk of high valuations. The shift towards more licensing deals rather than outright acquisitions is evident in the industry, with milestone-based payments limiting downside risks and enabling participation without overexposure.

Moreover, partnerships with China are on the rise, providing global firms with access to oncology pipelines while managing geopolitical risks. While US and European companies remain cautious about full acquisitions in China, licensing and co-development partnerships have doubled since 2020. These alliances offer a way to capitalize on scientific advancements while maintaining control and compliance in markets beyond China. The integration of new technologies, such as AI, is being increasingly leveraged in M&A activities to enhance intelligence and accelerate synergies.